Constellation Alpha Capital (PRIVATE.CNAC)

Overall impact
B (61)

Commentary

Constellation Alpha Capital is a strong overall performer. With a 'B' rating of 60.6 for overall impact (64th percentile compared to all companies), Constellation Alpha Capital ranks 10th out of 84 industry peers, behind Estre Ambiental, CM Seven Star Acquisition, Capitol Investment IV and 6 others, and ahead of Novume Solutions, MTech Acquisition, Chardan Healthcare Acquisition and 71 others. On top material causes for Constellation Alpha Capital's industry (Shell Companies), Constellation Alpha Capital performs poorly in Quality Lifelong Education (30.2 score). Constellation Alpha Capital did not receive an 'A' rating on any cause.
Impact
Cause PRIVATE.CNAC
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2015
Employees
2
Sector
Financials
Industry
Capital Markets
Sub-industry
Investment Banking & Brokerage
SASB industry
Investment Banking & Brokerage
Headquarters
Florida, United States
Share classes
PRIVATE.CNAC
CNAC
Description
DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. While the company generates revenue through laboratory services, it focuses on advancing its innovative testing solutions to improve patient outcomes and enhance the diagnostic process.
Material causes
Ethos considers the following causes material for Constellation Alpha Capital, based on its industry sub-industry Investment Banking & Brokerage. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.